{"id":6808,"date":"2023-04-24T17:17:25","date_gmt":"2023-04-24T15:17:25","guid":{"rendered":"https:\/\/www.izkf.med.fau.de\/?page_id=6808"},"modified":"2026-03-24T09:46:03","modified_gmt":"2026-03-24T08:46:03","slug":"tumorforschung","status":"publish","type":"page","link":"https:\/\/www.izkf.med.fau.de\/en\/projekte\/advancedprojects\/currentprojects\/tumorforschung\/","title":{"rendered":"Oncology"},"content":{"rendered":"<div class=\"wp-block-rrze-elements-collapsibles \"><div class=\"accordion\">\n<div class=\"wp-block-rrze-elements-collapse \"><div class=\"accordion-group \"><h2 class=\"accordion-heading\"><button class=\"accordion-toggle\" data-toggle=\"collapse\" data-name=\"d37-imke-atreya-department-of-medicine-1-acly-in-ibd-associated-cancer\" data-href=\"#d37-imke-atreya-department-of-medicine-1-acly-in-ibd-associated-cancer\" type=\"button\" aria-expanded=\"false\" aria-controls=\"d37-imke-atreya-department-of-medicine-1-acly-in-ibd-associated-cancer-section\" id=\"d37-imke-atreya-department-of-medicine-1-acly-in-ibd-associated-cancer\">D37: Imke Atreya, Department of Medicine 1 | ACLY in IBD-associated cancer<\/button><\/h2><div id=\"d37-imke-atreya-department-of-medicine-1-acly-in-ibd-associated-cancer-section\" class=\"accordion-body \" aria-labelledby=\"d37-imke-atreya-department-of-medicine-1-acly-in-ibd-associated-cancer\" role=\"region\" name=\"d37-imke-atreya-department-of-medicine-1-acly-in-ibd-associated-cancer\"><div class=\"accordion-inner clearfix\">\n\n<p>Term: 01.04.2023 &#8211; 31.03.2026<\/p>\n\n\n\n<p>Our preliminary data indicate a beneficial role of the metabolic enzyme ACLY in T cells in the AOM\/DSS-induced CAC (colitis-associated cancer) model, while published data implicate that upregulation of ACLY in colon tumor cells promotes metastasis. Thus, we aim on the development of clinically applicable strategies to trigger ACLY activity selectively in tumor-infiltrating T cells and will focus on the identification of those CAC patients, who could best benefit from an ACLY-targeting therapy.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><figure><img loading=\"lazy\" decoding=\"async\" class=\"alignnone wp-image-6299\" src=\"https:\/\/www.izkf.med.fau.de\/files\/2023\/02\/atreyaim-250x300.jpg\" alt=\"\" srcset=\"https:\/\/www.izkf.med.fau.de\/files\/2023\/02\/atreyaim-250x300.jpg 250w, https:\/\/www.izkf.med.fau.de\/files\/2023\/02\/atreyaim-853x1024.jpg 853w, https:\/\/www.izkf.med.fau.de\/files\/2023\/02\/atreyaim-768x922.jpg 768w, https:\/\/www.izkf.med.fau.de\/files\/2023\/02\/atreyaim-1279x1536.jpg 1279w, https:\/\/www.izkf.med.fau.de\/files\/2023\/02\/atreyaim-1706x2048.jpg 1706w, https:\/\/www.izkf.med.fau.de\/files\/2023\/02\/atreyaim-50x60.jpg 50w, https:\/\/www.izkf.med.fau.de\/files\/2023\/02\/atreyaim-92x110.jpg 92w, https:\/\/www.izkf.med.fau.de\/files\/2023\/02\/atreyaim-200x240.jpg 200w, https:\/\/www.izkf.med.fau.de\/files\/2023\/02\/atreyaim-267x320.jpg 267w, https:\/\/www.izkf.med.fau.de\/files\/2023\/02\/atreyaim-391x470.jpg 391w, https:\/\/www.izkf.med.fau.de\/files\/2023\/02\/atreyaim.jpg 1805w\" \/><\/figure><\/td><\/tr><tr><td><strong>Principal Investigator<\/strong><br>PD Dr. Imke Atreya<br>E-Mail: imke.atreya@uk-erlangen.de<\/td><\/tr><\/tbody><\/table><\/figure>\n\n<\/div><\/div><\/div><\/div>\n\n<div class=\"wp-block-rrze-elements-collapse \"><div class=\"accordion-group \"><h2 class=\"accordion-heading\"><button class=\"accordion-toggle\" data-toggle=\"collapse\" data-name=\"d38-anja-bosserhoff-institute-of-biochemistry-ap2e-in-malignant-melanoma\" data-href=\"#d38-anja-bosserhoff-institute-of-biochemistry-ap2e-in-malignant-melanoma\" type=\"button\" aria-expanded=\"false\" aria-controls=\"d38-anja-bosserhoff-institute-of-biochemistry-ap2e-in-malignant-melanoma-section\" id=\"d38-anja-bosserhoff-institute-of-biochemistry-ap2e-in-malignant-melanoma\">D38: Anja Bosserhoff, Institute of Biochemistry | AP2e in malignant melanoma<\/button><\/h2><div id=\"d38-anja-bosserhoff-institute-of-biochemistry-ap2e-in-malignant-melanoma-section\" class=\"accordion-body \" aria-labelledby=\"d38-anja-bosserhoff-institute-of-biochemistry-ap2e-in-malignant-melanoma\" role=\"region\" name=\"d38-anja-bosserhoff-institute-of-biochemistry-ap2e-in-malignant-melanoma\"><div class=\"accordion-inner clearfix\">\n\n<p>Term: 16.03.2023 &#8211; 15.03.2026 <\/p>\n\n\n\n<p>The transcription factor family AP2 has important functions in development. AP2e was discovered in cooperation with this PI. We newly observed delayed onset of tumorigenesis in a murine Ap2e-deficient melanoma model. This is supported by expression data showing induced AP2e mRNA expression in early tumor development and a correlation of high Ap2e expression with reduced overall survival. In the project, the role of Ap2e in development and progression of melanoma is explored in molecular detail.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><figure><img loading=\"lazy\" decoding=\"async\" class=\"alignnone wp-image-792\" src=\"https:\/\/www.izkf.med.fau.de\/files\/2017\/10\/Bosserhoff-e1579171357628-225x300.jpg\" alt=\"\" srcset=\"https:\/\/www.izkf.med.fau.de\/files\/2017\/10\/Bosserhoff-e1579171357628-225x300.jpg 225w, https:\/\/www.izkf.med.fau.de\/files\/2017\/10\/Bosserhoff-e1579171357628-60x80.jpg 60w, https:\/\/www.izkf.med.fau.de\/files\/2017\/10\/Bosserhoff-e1579171357628-90x120.jpg 90w, https:\/\/www.izkf.med.fau.de\/files\/2017\/10\/Bosserhoff-e1579171357628-180x240.jpg 180w, https:\/\/www.izkf.med.fau.de\/files\/2017\/10\/Bosserhoff-e1579171357628-240x320.jpg 240w, https:\/\/www.izkf.med.fau.de\/files\/2017\/10\/Bosserhoff-e1579171357628.jpg 266w\" \/><\/figure><\/td><\/tr><tr><td><strong>Principal Investigator<\/strong><br>Prof. Dr. Anja Bosserhoff<br>E-Mail: anja.bosserhoff@fau.de<\/td><\/tr><\/tbody><\/table><\/figure>\n\n<\/div><\/div><\/div><\/div>\n\n<div class=\"wp-block-rrze-elements-collapse \"><div class=\"accordion-group \"><h2 class=\"accordion-heading\"><button class=\"accordion-toggle\" data-toggle=\"collapse\" data-name=\"d39-simone-brabletz-chair-of-experimental-medicine-iemt-and-ferroptosis\" data-href=\"#d39-simone-brabletz-chair-of-experimental-medicine-iemt-and-ferroptosis\" type=\"button\" aria-expanded=\"false\" aria-controls=\"d39-simone-brabletz-chair-of-experimental-medicine-iemt-and-ferroptosis-section\" id=\"d39-simone-brabletz-chair-of-experimental-medicine-iemt-and-ferroptosis\">D39: Simone Brabletz, Chair of Experimental Medicine | IEMT and ferroptosis<\/button><\/h2><div id=\"d39-simone-brabletz-chair-of-experimental-medicine-iemt-and-ferroptosis-section\" class=\"accordion-body \" aria-labelledby=\"d39-simone-brabletz-chair-of-experimental-medicine-iemt-and-ferroptosis\" role=\"region\" name=\"d39-simone-brabletz-chair-of-experimental-medicine-iemt-and-ferroptosis\"><div class=\"accordion-inner clearfix\">\n\n<p>Term: 01.07.2023 &#8211; 30.06.2026 <\/p>\n\n\n\n<p>We have demonstrated that the EMT-activator ZEB1 provides cancer cells not only with aberrant motility, but also with survival traits enabling tumor progression, metastasis and drug resistance. Our aim is to eliminate these aggressive \u2018untargetable\u2019 EMT-state cancer cells, which strikingly show a high sensitivity to ferroptotic cell death. In this project, we want to elucidate the molecular basis of ZEB1 \u2013 associated ferroptosis sensitivity to exploit it as a novel therapeutic target.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><figure><img loading=\"lazy\" decoding=\"async\" class=\"alignnone wp-image-6300\" src=\"https:\/\/www.izkf.med.fau.de\/files\/2023\/02\/brabletzs-250x300.jpg\" alt=\"\" srcset=\"https:\/\/www.izkf.med.fau.de\/files\/2023\/02\/brabletzs-250x300.jpg 250w, https:\/\/www.izkf.med.fau.de\/files\/2023\/02\/brabletzs-853x1024.jpg 853w, https:\/\/www.izkf.med.fau.de\/files\/2023\/02\/brabletzs-768x922.jpg 768w, https:\/\/www.izkf.med.fau.de\/files\/2023\/02\/brabletzs-1280x1536.jpg 1280w, https:\/\/www.izkf.med.fau.de\/files\/2023\/02\/brabletzs-1707x2048.jpg 1707w, https:\/\/www.izkf.med.fau.de\/files\/2023\/02\/brabletzs-50x60.jpg 50w, https:\/\/www.izkf.med.fau.de\/files\/2023\/02\/brabletzs-92x110.jpg 92w, https:\/\/www.izkf.med.fau.de\/files\/2023\/02\/brabletzs-200x240.jpg 200w, https:\/\/www.izkf.med.fau.de\/files\/2023\/02\/brabletzs-267x320.jpg 267w, https:\/\/www.izkf.med.fau.de\/files\/2023\/02\/brabletzs-392x470.jpg 392w, https:\/\/www.izkf.med.fau.de\/files\/2023\/02\/brabletzs.jpg 1735w\" \/><\/figure><\/td><\/tr><tr><td><strong>Principal Investigator<\/strong><br>Dr. Simone Brabletz<br>E-Mail: simone.brabletz@fau.de<\/td><\/tr><\/tbody><\/table><\/figure>\n\n<\/div><\/div><\/div><\/div>\n\n<div class=\"wp-block-rrze-elements-collapse \"><div class=\"accordion-group \"><h2 class=\"accordion-heading\"><button class=\"accordion-toggle\" data-toggle=\"collapse\" data-name=\"d40-peter-dietrich-department-of-medicine-1-the-role-of-ddx46-in-liver-cancer\" data-href=\"#d40-peter-dietrich-department-of-medicine-1-the-role-of-ddx46-in-liver-cancer\" type=\"button\" aria-expanded=\"false\" aria-controls=\"d40-peter-dietrich-department-of-medicine-1-the-role-of-ddx46-in-liver-cancer-section\" id=\"d40-peter-dietrich-department-of-medicine-1-the-role-of-ddx46-in-liver-cancer\">D40: Peter Dietrich, Department of Medicine 1 | The role of DDX46 in liver cancer<\/button><\/h2><div id=\"d40-peter-dietrich-department-of-medicine-1-the-role-of-ddx46-in-liver-cancer-section\" class=\"accordion-body \" aria-labelledby=\"d40-peter-dietrich-department-of-medicine-1-the-role-of-ddx46-in-liver-cancer\" role=\"region\" name=\"d40-peter-dietrich-department-of-medicine-1-the-role-of-ddx46-in-liver-cancer\"><div class=\"accordion-inner clearfix\">\n\n<p>Term: 01.03.2023 &#8211; 28.02.2026<\/p>\n\n\n\n<p>The neuropeptide Y (NPY) system was shown by the applicant to be a major driver of HCC. Transcriptome screening revealed that DEAD-box RNA helicase DDX46 is a novel and attractive NPY-regulated target in HCC. The major aims of this study are to characterize NPY-mediated regulation of DDX46 and to decipher the role of DDX46 as a novel and promising diagnostic and therapeutic target in HCC. <\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><figure><img loading=\"lazy\" decoding=\"async\" class=\"alignnone wp-image-1244\" src=\"https:\/\/www.izkf.med.fau.de\/files\/2017\/10\/Dietrich-e1579171697832-225x300.jpg\" alt=\"\" srcset=\"https:\/\/www.izkf.med.fau.de\/files\/2017\/10\/Dietrich-e1579171697832-225x300.jpg 225w, https:\/\/www.izkf.med.fau.de\/files\/2017\/10\/Dietrich-e1579171697832-60x80.jpg 60w, https:\/\/www.izkf.med.fau.de\/files\/2017\/10\/Dietrich-e1579171697832-90x120.jpg 90w, https:\/\/www.izkf.med.fau.de\/files\/2017\/10\/Dietrich-e1579171697832-180x240.jpg 180w, https:\/\/www.izkf.med.fau.de\/files\/2017\/10\/Dietrich-e1579171697832-240x320.jpg 240w, https:\/\/www.izkf.med.fau.de\/files\/2017\/10\/Dietrich-e1579171697832.jpg 266w\" \/><\/figure><\/td><\/tr><tr><td><strong>Principal Investigator<\/strong><br>PD Dr. Dr. Peter Dietrich<br>E-Mail: peter.dietrich@uk-erlangen.de<\/td><\/tr><\/tbody><\/table><\/figure>\n\n<\/div><\/div><\/div><\/div>\n\n<div class=\"wp-block-rrze-elements-collapse \"><div class=\"accordion-group \"><h2 class=\"accordion-heading\"><button class=\"accordion-toggle\" data-toggle=\"collapse\" data-name=\"d41-felix-engel-department-of-nephropathology-markus-eckstein-institute-of-pathology-therapy-resistance-in-urothelial-cancer\" data-href=\"#d41-felix-engel-department-of-nephropathology-markus-eckstein-institute-of-pathology-therapy-resistance-in-urothelial-cancer\" type=\"button\" aria-expanded=\"false\" aria-controls=\"d41-felix-engel-department-of-nephropathology-markus-eckstein-institute-of-pathology-therapy-resistance-in-urothelial-cancer-section\" id=\"d41-felix-engel-department-of-nephropathology-markus-eckstein-institute-of-pathology-therapy-resistance-in-urothelial-cancer\">D41: Felix Engel, Department of Nephropathology | Markus Eckstein, Institute of Pathology | Therapy resistance in urothelial cancer<\/button><\/h2><div id=\"d41-felix-engel-department-of-nephropathology-markus-eckstein-institute-of-pathology-therapy-resistance-in-urothelial-cancer-section\" class=\"accordion-body \" aria-labelledby=\"d41-felix-engel-department-of-nephropathology-markus-eckstein-institute-of-pathology-therapy-resistance-in-urothelial-cancer\" role=\"region\" name=\"d41-felix-engel-department-of-nephropathology-markus-eckstein-institute-of-pathology-therapy-resistance-in-urothelial-cancer\"><div class=\"accordion-inner clearfix\">\n\n<p>Term: 01.07.2023 &#8211; 30.06.2026 <\/p>\n\n\n\n<p>Urothelial carcinoma (UC) is among the ten most common cancers worldwide and overall therapy systemic response rates are limited (~20%). Molecular insights in processes driving therapy resistance are scarce. Here, we propose to expand our existing patient-derived living UC biobank, develop a novel zebrafish model to study the role of fatty acid metabolism and ferroptosis in UC, and to determine if the zebrafish allows the pre-selection of therapy responsive patients.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><figure><img loading=\"lazy\" decoding=\"async\" class=\"alignnone wp-image-839\" src=\"https:\/\/www.izkf.med.fau.de\/files\/2017\/10\/Engel-e1579174236481-231x300.jpg\" alt=\"\" srcset=\"https:\/\/www.izkf.med.fau.de\/files\/2017\/10\/Engel-e1579174236481-231x300.jpg 231w, https:\/\/www.izkf.med.fau.de\/files\/2017\/10\/Engel-e1579174236481-185x240.jpg 185w, https:\/\/www.izkf.med.fau.de\/files\/2017\/10\/Engel-e1579174236481-247x320.jpg 247w, https:\/\/www.izkf.med.fau.de\/files\/2017\/10\/Engel-e1579174236481.jpg 273w\" \/><\/figure><\/td><td><figure><img loading=\"lazy\" decoding=\"async\" class=\"alignnone wp-image-6011\" src=\"https:\/\/www.izkf.med.fau.de\/files\/2022\/11\/Eckstein-250x300.jpg\" alt=\"\" srcset=\"https:\/\/www.izkf.med.fau.de\/files\/2022\/11\/Eckstein-250x300.jpg 250w, https:\/\/www.izkf.med.fau.de\/files\/2022\/11\/Eckstein-50x60.jpg 50w, https:\/\/www.izkf.med.fau.de\/files\/2022\/11\/Eckstein.jpg 295w, https:\/\/www.izkf.med.fau.de\/files\/2022\/11\/Eckstein-92x110.jpg 92w, https:\/\/www.izkf.med.fau.de\/files\/2022\/11\/Eckstein-200x240.jpg 200w, https:\/\/www.izkf.med.fau.de\/files\/2022\/11\/Eckstein-267x320.jpg 267w\" \/><\/figure><\/td><\/tr><tr><td><strong>Principal Investigator<\/strong><br>Prof. Dr. Felix Engel<br>E-Mail: felix.engel@uk-erlangen.de<\/td><td><strong>Principal Investigator<\/strong><br>Dr. Markus Eckstein<br>E-Mail: markus.eckstein@uk-erlangen.de<\/td><\/tr><\/tbody><\/table><\/figure>\n\n<\/div><\/div><\/div><\/div>\n\n<div class=\"wp-block-rrze-elements-collapse \"><div class=\"accordion-group \"><h2 class=\"accordion-heading\"><button class=\"accordion-toggle\" data-toggle=\"collapse\" data-name=\"d42-anja-bosserhoff-claus-hellerbrand-institute-of-biochemistry-psap-in-liver-steatosis-triggered-liver-cancer\" data-href=\"#d42-anja-bosserhoff-claus-hellerbrand-institute-of-biochemistry-psap-in-liver-steatosis-triggered-liver-cancer\" type=\"button\" aria-expanded=\"false\" aria-controls=\"d42-anja-bosserhoff-claus-hellerbrand-institute-of-biochemistry-psap-in-liver-steatosis-triggered-liver-cancer-section\" id=\"d42-anja-bosserhoff-claus-hellerbrand-institute-of-biochemistry-psap-in-liver-steatosis-triggered-liver-cancer\">D42: Anja Bosserhoff; Claus Hellerbrand \u2020, Institute of Biochemistry | PSAP in liver steatosis-triggered liver cancer<\/button><\/h2><div id=\"d42-anja-bosserhoff-claus-hellerbrand-institute-of-biochemistry-psap-in-liver-steatosis-triggered-liver-cancer-section\" class=\"accordion-body \" aria-labelledby=\"d42-anja-bosserhoff-claus-hellerbrand-institute-of-biochemistry-psap-in-liver-steatosis-triggered-liver-cancer\" role=\"region\" name=\"d42-anja-bosserhoff-claus-hellerbrand-institute-of-biochemistry-psap-in-liver-steatosis-triggered-liver-cancer\"><div class=\"accordion-inner clearfix\">\n\n<p>Term: 01.04.2023 &#8211; 31.03.2026 <\/p>\n\n\n\n<p>Non-alcoholic fatty liver disease (NAFLD) is the leading cause of hepatocellular carcinoma (HCC). Furthermore, NAFLD promotes HCC progression but the mechanism are elusive.<br>Our preliminary work indicates that enhanced expression of prosaposin (PSAP) in NAFLD promotes HCC growth.<br>Therefore, this project aims to characterize the molecular mechanisms by which PSAP affects HCC cells, to test the therapeutic potential of PSAP inhibition and to validate the function of PSAP in clinical HCC samples.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><figure><img loading=\"lazy\" decoding=\"async\" class=\"alignnone wp-image-792\" src=\"https:\/\/www.izkf.med.fau.de\/files\/2017\/10\/Bosserhoff-e1579171357628-225x300.jpg\" alt=\"\" srcset=\"https:\/\/www.izkf.med.fau.de\/files\/2017\/10\/Bosserhoff-e1579171357628-225x300.jpg 225w, https:\/\/www.izkf.med.fau.de\/files\/2017\/10\/Bosserhoff-e1579171357628-60x80.jpg 60w, https:\/\/www.izkf.med.fau.de\/files\/2017\/10\/Bosserhoff-e1579171357628-90x120.jpg 90w, https:\/\/www.izkf.med.fau.de\/files\/2017\/10\/Bosserhoff-e1579171357628-180x240.jpg 180w, https:\/\/www.izkf.med.fau.de\/files\/2017\/10\/Bosserhoff-e1579171357628-240x320.jpg 240w, https:\/\/www.izkf.med.fau.de\/files\/2017\/10\/Bosserhoff-e1579171357628.jpg 266w\" \/><\/figure><\/td><\/tr><tr><td><strong>Principal Investigator<\/strong><br>Prof. Dr. Anja Bosserhoff<br>E-Mail: anja.bosserhoff@fau.de<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><figure><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-5412\" src=\"https:\/\/www.izkf.med.fau.de\/files\/2022\/02\/hellerbrand_neu-238x300.jpg\" alt=\"\" srcset=\"https:\/\/www.izkf.med.fau.de\/files\/2022\/02\/hellerbrand_neu-238x300.jpg 238w, https:\/\/www.izkf.med.fau.de\/files\/2022\/02\/hellerbrand_neu-813x1024.jpg 813w, https:\/\/www.izkf.med.fau.de\/files\/2022\/02\/hellerbrand_neu-768x967.jpg 768w, https:\/\/www.izkf.med.fau.de\/files\/2022\/02\/hellerbrand_neu-191x240.jpg 191w, https:\/\/www.izkf.med.fau.de\/files\/2022\/02\/hellerbrand_neu-254x320.jpg 254w, https:\/\/www.izkf.med.fau.de\/files\/2022\/02\/hellerbrand_neu-373x470.jpg 373w, https:\/\/www.izkf.med.fau.de\/files\/2022\/02\/hellerbrand_neu.jpg 942w\" \/><\/figure><\/td><\/tr><tr><td><strong>Principal Investigator<\/strong><br>Prof. Dr. Claus Hellerbrand \u2020<br>E-Mail: claus.hellerbrand@fau.de<\/td><\/tr><\/tbody><\/table><\/figure>\n\n<\/div><\/div><\/div><\/div>\n\n<div class=\"wp-block-rrze-elements-collapse \"><div class=\"accordion-group \"><h2 class=\"accordion-heading\"><button class=\"accordion-toggle\" data-toggle=\"collapse\" data-name=\"d43-simon-voelkl-department-of-medicine-5-julio-vera-gonzlez-department-of-dermatology-regulation-of-cd19car-t-cells\" data-href=\"#d43-simon-voelkl-department-of-medicine-5-julio-vera-gonzlez-department-of-dermatology-regulation-of-cd19car-t-cells\" type=\"button\" aria-expanded=\"false\" aria-controls=\"d43-simon-voelkl-department-of-medicine-5-julio-vera-gonzlez-department-of-dermatology-regulation-of-cd19car-t-cells-section\" id=\"d43-simon-voelkl-department-of-medicine-5-julio-vera-gonzlez-department-of-dermatology-regulation-of-cd19car-t-cells\">D43: Simon V\u00f6lkl, Department of Medicine 5 | Julio Vera Gonz\u00e1lez, Department of Dermatology | Regulation of CD19.CAR T-cells<\/button><\/h2><div id=\"d43-simon-voelkl-department-of-medicine-5-julio-vera-gonzlez-department-of-dermatology-regulation-of-cd19car-t-cells-section\" class=\"accordion-body \" aria-labelledby=\"d43-simon-voelkl-department-of-medicine-5-julio-vera-gonzlez-department-of-dermatology-regulation-of-cd19car-t-cells\" role=\"region\" name=\"d43-simon-voelkl-department-of-medicine-5-julio-vera-gonzlez-department-of-dermatology-regulation-of-cd19car-t-cells\"><div class=\"accordion-inner clearfix\">\n\n<p>Term: 16.03.2023 &#8211; 15.03.2026 <\/p>\n\n\n\n<p>CD19-directed chimeric antigen receptor (CAR) T-cells have shown high efficacy in the treatment of B-cell malignancies and are now emerging as a standard approach for patients with relapsed and refractory disease. Despite this progress, a significant portion of patients still experience resistance to treatment. We aim to understand the intrinsic mechanisms controlling persistence and effector functions of CAR T-cells and therefore identify strategies to overcome treatment failure.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><figure><img loading=\"lazy\" decoding=\"async\" class=\"alignnone wp-image-6301\" src=\"https:\/\/www.izkf.med.fau.de\/files\/2023\/02\/Voelkl-250x300.jpg\" alt=\"\" srcset=\"https:\/\/www.izkf.med.fau.de\/files\/2023\/02\/Voelkl-250x300.jpg 250w, https:\/\/www.izkf.med.fau.de\/files\/2023\/02\/Voelkl-50x60.jpg 50w, https:\/\/www.izkf.med.fau.de\/files\/2023\/02\/Voelkl.jpg 295w, https:\/\/www.izkf.med.fau.de\/files\/2023\/02\/Voelkl-92x110.jpg 92w, https:\/\/www.izkf.med.fau.de\/files\/2023\/02\/Voelkl-200x240.jpg 200w, https:\/\/www.izkf.med.fau.de\/files\/2023\/02\/Voelkl-267x320.jpg 267w\" \/><\/figure><\/td><td><figure><img loading=\"lazy\" decoding=\"async\" class=\"alignnone wp-image-6302\" src=\"https:\/\/www.izkf.med.fau.de\/files\/2023\/02\/vera-gonzalez-226x300.jpg\" alt=\"\" srcset=\"https:\/\/www.izkf.med.fau.de\/files\/2023\/02\/vera-gonzalez-226x300.jpg 226w, https:\/\/www.izkf.med.fau.de\/files\/2023\/02\/vera-gonzalez-770x1024.jpg 770w, https:\/\/www.izkf.med.fau.de\/files\/2023\/02\/vera-gonzalez-768x1021.jpg 768w, https:\/\/www.izkf.med.fau.de\/files\/2023\/02\/vera-gonzalez-120x160.jpg 120w, https:\/\/www.izkf.med.fau.de\/files\/2023\/02\/vera-gonzalez-240x320.jpg 240w, https:\/\/www.izkf.med.fau.de\/files\/2023\/02\/vera-gonzalez-45x60.jpg 45w, https:\/\/www.izkf.med.fau.de\/files\/2023\/02\/vera-gonzalez-83x110.jpg 83w, https:\/\/www.izkf.med.fau.de\/files\/2023\/02\/vera-gonzalez-181x240.jpg 181w, https:\/\/www.izkf.med.fau.de\/files\/2023\/02\/vera-gonzalez-241x320.jpg 241w, https:\/\/www.izkf.med.fau.de\/files\/2023\/02\/vera-gonzalez-354x470.jpg 354w, https:\/\/www.izkf.med.fau.de\/files\/2023\/02\/vera-gonzalez.jpg 1044w\" \/><\/figure><\/td><\/tr><tr><td><strong>Principal Investigator<\/strong><br>PD Dr. Simon V\u00f6lkl<br>E-Mail: simon.voelkl@uk-erlangen.de<\/td><td><strong>Principal Investigator<\/strong><br>Prof. Dr. Julio Vera Gonzalez,<br>E-Mail: julio.vera-gonzalez@uk-erlangen.de<\/td><\/tr><\/tbody><\/table><\/figure>\n\n<\/div><\/div><\/div><\/div>\n\n<div class=\"wp-block-rrze-elements-collapse \"><div class=\"accordion-group \"><h2 class=\"accordion-heading\"><button class=\"accordion-toggle\" data-toggle=\"collapse\" data-name=\"panel_b62d312e\" data-href=\"#panel_b62d312e\" type=\"button\" aria-expanded=\"false\" aria-controls=\"panel_b62d312e-section\" id=\"panel_b62d312e\">D44: Claudia G\u00fcnther, Department of Medicine 1 | Elisabeth Naschberger, Department of Surgery | Shaping the Colorectal Niche<\/button><\/h2><div id=\"panel_b62d312e-section\" class=\"accordion-body \" aria-labelledby=\"panel_b62d312e\" role=\"region\" name=\"panel_b62d312e\"><div class=\"accordion-inner clearfix\">\n\n<p>Term: Not started yet<\/p>\n\n\n<div class=\"alert clearfix clear alert-info \" title=\"\">\n\n<p>The gut microbiota is a key contributor to colorectal cancer (CRC). Our data suggest that bacterial nanoparticles act as shuttles delivering microbial effectors to intestinal stem cells. We hypothesize that they promote CRC initiation and progression by transferring genotoxins and modulating the tumor microenvironment. This project aims to dissect how bacterial nanoparticles influence tumor cells and the TME.<\/p>\n\n<\/div>\n<\/div><\/div><\/div><\/div>\n\n<div class=\"wp-block-rrze-elements-collapse \"><div class=\"accordion-group \"><h2 class=\"accordion-heading\"><button class=\"accordion-toggle\" data-toggle=\"collapse\" data-name=\"panel_a8f415d2\" data-href=\"#panel_a8f415d2\" type=\"button\" aria-expanded=\"false\" aria-controls=\"panel_a8f415d2-section\" id=\"panel_a8f415d2\">D45: Reiner Strick, Department of Obstetrics and Gynaecology | Markus Eckstein, Institute of Pathology | Regulation of S100A8\/A9 in bladder cancer<\/button><\/h2><div id=\"panel_a8f415d2-section\" class=\"accordion-body \" aria-labelledby=\"panel_a8f415d2\" role=\"region\" name=\"panel_a8f415d2\"><div class=\"accordion-inner clearfix\">\n\n<p>Term: Not started yet<\/p>\n\n\n<div class=\"alert clearfix clear alert-info \" title=\"\">\n\n<p>We demonstrate inflammation of 218 urothelial bladder cancers is driven by the Endogenous Retrovirus interferon axis and identify five clusters. Cytokines S100A8\/A9 were the highest significantly differentially expressed genes. S100A8\/A9 also function in the nucleus and transcriptionally co-activate ERVs, but repress interferon stimulated genes. Analyses of bladder tumors for inflammation, S100A8\/A9 and ERVs will help to understand tumor progression and maintenance predicting clinical outcome.<\/p>\n\n<\/div>\n<\/div><\/div><\/div><\/div>\n<\/div><\/div>\n\n\n\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1355,"featured_media":0,"parent":6778,"menu_order":2,"comment_status":"closed","ping_status":"closed","template":"page-templates\/page-subnav.php","meta":{"_rrze_cache":"enabled","_access_permission":"","_rrze_multilang_single_locale":"en_GB","_rrze_multilang_single_source":"https:\/\/www.izkf.med.fau.de\/?page_id=576","footnotes":""},"page_category":[154],"page_tag":[],"workflow_usergroup":[],"class_list":["post-6808","page","type-page","status-publish","hentry","page_category-general","en-GB"],"_links":{"self":[{"href":"https:\/\/www.izkf.med.fau.de\/wp-json\/wp\/v2\/pages\/6808","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.izkf.med.fau.de\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.izkf.med.fau.de\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.izkf.med.fau.de\/wp-json\/wp\/v2\/users\/1355"}],"replies":[{"embeddable":true,"href":"https:\/\/www.izkf.med.fau.de\/wp-json\/wp\/v2\/comments?post=6808"}],"version-history":[{"count":9,"href":"https:\/\/www.izkf.med.fau.de\/wp-json\/wp\/v2\/pages\/6808\/revisions"}],"predecessor-version":[{"id":131704,"href":"https:\/\/www.izkf.med.fau.de\/wp-json\/wp\/v2\/pages\/6808\/revisions\/131704"}],"up":[{"embeddable":true,"href":"https:\/\/www.izkf.med.fau.de\/wp-json\/wp\/v2\/pages\/6778"}],"wp:attachment":[{"href":"https:\/\/www.izkf.med.fau.de\/wp-json\/wp\/v2\/media?parent=6808"}],"wp:term":[{"taxonomy":"page_category","embeddable":true,"href":"https:\/\/www.izkf.med.fau.de\/wp-json\/wp\/v2\/page_category?post=6808"},{"taxonomy":"page_tag","embeddable":true,"href":"https:\/\/www.izkf.med.fau.de\/wp-json\/wp\/v2\/page_tag?post=6808"},{"taxonomy":"workflow_usergroup","embeddable":true,"href":"https:\/\/www.izkf.med.fau.de\/wp-json\/wp\/v2\/workflow_usergroup?post=6808"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}